Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The company has the passion and determination to develop new medicines that help improve and extend the lives of people living with cancer.
Bracco Diagnostics Inc. (BDI), the U.S.-based subsidiary of Bracco Imaging SpA, and part of the Bracco Group, is a leader in innovative imaging agents. Bracco offers a product and solution portfolio for all key diagnostic imaging modalities: X-Ray Imaging, Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers.
Bracco nuclear medicine offers specialty radiopharmaceuticals for cardiac PET and hepatobiliary imaging. A decades-long legacy of excellence through research, innovation and clinical expertise has earned Bracco a reputation as the market leader in cardiac PET imaging.
Find out how our solutions, expertise and experience can help you and your patients.
CDL is the most trusted turnkey PET and PET/CT solutions provider in the United States. From customized PET/CT suite builds in approximately 180 days to our flexible mobile rubidium programs, CDL is dedicated to partnering with cardiologists and institutions to make the best diagnostic care accessible for cardiac patients everywhere.
Curium is the world’s largest nuclear medicine company. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence and unparalleled service. To learn more, visit www.curiumpharma.com
Lantheus Medical Imaging (www.lantheus.com) is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products.
Life Molecular Imaging (LMI) strives to be a leader in the Molecular Imaging field by developing innovative products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. LMI is now a part of the Alliance Medical Molecular Imaging division whose combined services allow physicians, pharma industry and academia greater access to established and innovative imaging agents for clinical trials and clinical routine.
At Advanced Accelerator Applications (AAA), a Novartis company, we are reimagining nuclear medicine and cancer care. Our mission is to transform patients’ lives by developing and delivering targeted radioligand therapies and precision imaging radioligands for oncology.
Telix is a global, commercial-stage biopharmaceutical company focused on the development of diagnostic and therapeutic (‘theranostic’) products using targeted radiation
Hermes Medical Solutions enables precise reporting for all clinical specialties, performed from ONE user-friendly environment with the help of AI-driven decision support and multimodality fusion tools. We empower you as physicians & healthcare professionals with the data and tools needed, enabling faster, more personalized diagnosis and treatment for your patients.
MIM Software offers a comprehensive suite of applications to support Radiology and Nuclear Medicine’s important role in the patient care pathway. MIM Software products emphasize the importance of quantitation, collaboration, and data management to provide physicians with the information needed to excel in theranostics, generate confident clinical guidance, and inform effective treatments.
NorthStar Medical Radioisotopes is a commercial-stage nuclear medicine company that manufactures and distributes diagnostic and therapeutic radiopharmaceuticals. The Company’s proprietary state-of-the art technology and proven management team have propelled it to the forefront of U.S. medical radioisotope production as the sole domestic producer of the diagnostic imaging radioisotope molybdenum-99 (Mo-99). Mo-99 is used to generate technetium-99m (Tc-99m), the standard of care in diagnostic imaging to assess the extent and severity of heart disease and cancer. NorthStar’s unique Mo-99 production process is non-uranium based and environmentally friendly. NorthStar is expanding its industry-leading position in the emerging area of therapeutic radioisotopes, which are used in targeted radiopharmaceutical therapy to treat cancer, respiratory and other diseases. Using first-in-kind and environmentally-sound electron accelerator technology, NorthStar is poised to be the first commercial-scale producer of therapeutic radioisotopes actinium-225 (Ac-225) and copper-67 (Cu-67). For more information about NorthStar’s comprehensive radiopharmaceutical portfolio, visit: www.northstarnm.com.
Spectrum Dynamics is spearheading the transformation of SPECT imaging systems from analog to digital technology with D-SPECT and VERITON-CT scanners, providing clinicians a tool kit for disease diagnosis and management.
Spectrum digital scanners: -World first digital cardiac system, D-SPECT® CARDIO -World first 360 CZT ring-shaped gantry digital SPECT-CT, VERITON-CT®
Syntermed is a leading provider of innovative software and workflow solutions for cardiology, neurology, radiology, and most recently oncology. Its Emory Toolbox™, NeuroQ™, and Syntermed Live™ solutions are some of the most widely used and recognized solutions for the analysis of SPECT, PET, and CT studies worldwide.